{
    "abstract": "Influenza is a viral infection that affects much of the global population each year. Vaccination remains the most effective tool for preventing the disease. Live attenuated influenza vaccine (LAIV) has been used since the 1950s to protect humans against seasonal influenza. LAIVs developed by the Institute of Experimental Medicine (IEM), Saint Petersburg, Russia, have been successfully used in Russia since 1987. In 2006, the World Health Organization (WHO) announced a Global action plan for influenza vaccines (GAP). WHO, recognizing potential advantages of LAIV over the inactivated influenza vaccine in a pandemic situation, included LAIV in the GAP. BioDiem Ltd., a vaccine development company based in Melbourne, Australia which held the rights for the Russian LAIV, licensed this technology to WHO in 2009. WHO was permitted to grant sub-licenses to vaccine manufacturers in newly industrialized and developing countries to use the Russian LAIV for the development, manufacture, use and sale of pandemic and seasonal LAIVs. To date, WHO has granted sub-licenses to vaccine manufacturers in China (Changchun BCHT Biotechnology Co., Ltd.), India (Serum Institute of India Pvt. Ltd.) and Thailand (Government Pharmaceutical Organization). In parallel, in 2009, IEM signed an agreement with WHO, under which IEM committed to supply pandemic and seasonal candidate vaccine viruses to the sub-licensees. This paper describes the progress made by collaborators from China, India, Russia and Thailand in developing preventive measures, including LAIV against pandemic influenza.",
    "author_highlights": [
        {
            "endOffset": 12330,
            "sentence": "LAIV has been used in Russia for decades.",
            "startOffset": 12289
        },
        {
            "endOffset": 12414,
            "sentence": "Russian LAIV consistently provides superior effective protection against influenza.",
            "startOffset": 12331
        },
        {
            "endOffset": 12486,
            "sentence": "It was incorporated into the WHO global pandemic influenza action plan.",
            "startOffset": 12415
        },
        {
            "endOffset": 12567,
            "sentence": "A number of Russian LAIVs against pandemic influenza viruses have been prepared.",
            "startOffset": 12487
        },
        {
            "endOffset": 12644,
            "sentence": "Russian LAIV technology was transferred to a number of developing countries.",
            "startOffset": 12568
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "Marie Paule",
                    "initial": "M.P.",
                    "last": "Kieny"
                },
                {
                    "first": "Alejandro",
                    "initial": "A.",
                    "last": "Costa"
                },
                {
                    "first": "Joachim",
                    "initial": "J.",
                    "last": "Hombach"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Carrasco"
                },
                {
                    "first": "Yuri",
                    "initial": "Y.",
                    "last": "Pervikov"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Salisbury"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Greco"
                },
                {
                    "first": "Ian",
                    "initial": "I.",
                    "last": "Gust"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "LaForce"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Franco-Paredes"
                },
                {
                    "first": "Jos\u00e9 Ignacio",
                    "initial": "J.I.",
                    "last": "Santos"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "D'Hondt"
                },
                {
                    "first": "Guus",
                    "initial": "G.",
                    "last": "Rimmelzwaan"
                },
                {
                    "first": "Ruth",
                    "initial": "R.",
                    "last": "Karron"
                },
                {
                    "first": "Keiji",
                    "initial": "K.",
                    "last": "Fukuda"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.07.021",
            "firstpage": "6367",
            "issn": "0264410X",
            "lastpage": "6370",
            "pmid": "17240560",
            "pub_year": 2006,
            "title": "A global pandemic influenza vaccine action plan",
            "volume": "24"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Han",
                    "initial": "H.",
                    "last": "van den Bosch"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Mironov"
                },
                {
                    "first": "Anatoly",
                    "initial": "A.",
                    "last": "Naikhin"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Larionova"
                },
                {
                    "first": "Dimitry",
                    "initial": "D.",
                    "last": "Bushmenkov"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.04.122",
            "firstpage": "A40",
            "issn": "0264410X",
            "lastpage": "A44",
            "pmid": "21684428",
            "pub_year": 2011,
            "title": "Live attenuated pandemic influenza vaccine: Clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries",
            "volume": "29"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Shcherbik"
                },
                {
                    "first": "Nicholas",
                    "initial": "N.",
                    "last": "Pearce"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Larionova"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Xiyan",
                    "initial": "X.",
                    "last": "Xu"
                },
                {
                    "first": "David E.",
                    "initial": "D.E.",
                    "last": "Wentworth"
                },
                {
                    "first": "Tatiana",
                    "initial": "T.",
                    "last": "Bousse"
                }
            ],
            "doi": "10.1016/j.jviromet.2015.10.009",
            "firstpage": "33",
            "issn": "01660934",
            "lastpage": "39",
            "pmid": "26519883",
            "pub_year": 2016,
            "title": "Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses",
            "volume": "227"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Shcherbik"
                },
                {
                    "first": "Nicholas",
                    "initial": "N.",
                    "last": "Pearce"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Balish"
                },
                {
                    "first": "Joyce",
                    "initial": "J.",
                    "last": "Jones"
                },
                {
                    "first": "Sharmi",
                    "initial": "S.",
                    "last": "Thor"
                },
                {
                    "first": "Charles Todd",
                    "initial": "C.T.",
                    "last": "Davis"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Pearce"
                },
                {
                    "first": "Terrence",
                    "initial": "T.",
                    "last": "Tumpey"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Cureton"
                },
                {
                    "first": "Li Mei",
                    "initial": "L.M.",
                    "last": "Chen"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Villanueva"
                },
                {
                    "first": "Tatiana L.",
                    "initial": "T.L.",
                    "last": "Bousse"
                }
            ],
            "doi": "10.1371/journal.pone.0138951",
            "issn": "19326203",
            "pmid": "26405798",
            "pub_year": 2015,
            "title": "Generation and characterization of live attenuated influenza A(H7N9) candidate vaccine virus based on Russian donor of attenuation",
            "volume": "10"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Svetlana V.",
                    "initial": "S.V.",
                    "last": "Shcherbik"
                },
                {
                    "first": "Nicholas C.",
                    "initial": "N.C.",
                    "last": "Pearce"
                },
                {
                    "first": "Marnie L.",
                    "initial": "M.L.",
                    "last": "Levine"
                },
                {
                    "first": "Alexander I.",
                    "initial": "A.I.",
                    "last": "Klimov"
                },
                {
                    "first": "Julie M.",
                    "initial": "J.M.",
                    "last": "Villanueva"
                },
                {
                    "first": "Tatiana L.",
                    "initial": "T.L.",
                    "last": "Bousse"
                }
            ],
            "doi": "10.1371/journal.pone.0092580",
            "issn": "19326203",
            "pmid": "24647786",
            "pub_year": 2014,
            "title": "Rapid strategy for screening by pyrosequencing of influenza virus reassortants - Candidates for live attenuated vaccines",
            "volume": "9"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Shcherbik"
                },
                {
                    "first": "Sheila B.",
                    "initial": "S.B.",
                    "last": "Sergent"
                },
                {
                    "first": "William G.",
                    "initial": "W.G.",
                    "last": "Davis"
                },
                {
                    "first": "Bo",
                    "initial": "B.",
                    "last": "Shu"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Barnes"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Larionova"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Klimov"
                },
                {
                    "first": "Tatiana",
                    "initial": "T.",
                    "last": "Bousse"
                }
            ],
            "doi": "10.1016/j.jviromet.2013.09.003",
            "firstpage": "18",
            "issn": "01660934",
            "lastpage": "25",
            "pmid": "24056261",
            "pub_year": 2014,
            "title": "Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production",
            "volume": "195"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Larionova"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Andrey",
                    "initial": "A.",
                    "last": "Rekstin"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Dubrovina"
                },
                {
                    "first": "Ekaterina",
                    "initial": "E.",
                    "last": "Bazhenova"
                },
                {
                    "first": "Ted M.",
                    "initial": "T.M.",
                    "last": "Ross"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Swayne"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Gubareva"
                },
                {
                    "first": "Vadim",
                    "initial": "V.",
                    "last": "Tsvetnitsky"
                },
                {
                    "first": "Ekaterina",
                    "initial": "E.",
                    "last": "Fedorova"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Doroshenko"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                }
            ],
            "doi": "10.4172/2157-7560.1000208",
            "issn": "21577560",
            "pub_year": 2013,
            "title": "Live attenuated influenza vaccines against highly pathogenic H5N1avian influenza: Development and preclinical characterization",
            "volume": "4"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "J\u00f8rgen",
                    "initial": "J.",
                    "last": "De Jonge"
                },
                {
                    "first": "Tatiana",
                    "initial": "T.",
                    "last": "Smolonogina"
                },
                {
                    "first": "Andrey",
                    "initial": "A.",
                    "last": "Rekstin"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Van Amerongen"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Van Dijken"
                },
                {
                    "first": "Justin",
                    "initial": "J.",
                    "last": "Mouthaan"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Roholl"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Kuznetsova"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Doroshenko"
                },
                {
                    "first": "Vadim",
                    "initial": "V.",
                    "last": "Tsvetnitsky"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                }
            ],
            "doi": "10.1371/journal.pone.0102339",
            "issn": "19326203",
            "pmid": "25058039",
            "pub_year": 2014,
            "title": "Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus",
            "volume": "9"
        },
        "b0055": {
            "authors": [
                {
                    "first": "J\u00d8rgen",
                    "initial": "J.",
                    "last": "De Jonge"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Van Dijken"
                },
                {
                    "first": "Sanne",
                    "initial": "S.",
                    "last": "Spijkers"
                },
                {
                    "first": "Justin",
                    "initial": "J.",
                    "last": "Mouthaan"
                },
                {
                    "first": "Rineke",
                    "initial": "R.",
                    "last": "De Jong"
                },
                {
                    "first": "Tatiana",
                    "initial": "T.",
                    "last": "Smolonogina"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Roholl"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                }
            ],
            "doi": "10.1038/mt.2016.23",
            "firstpage": "991",
            "issn": "15250016",
            "lastpage": "1002",
            "pmid": "26796670",
            "pub_year": 2016,
            "title": "H7N9 live attenuated influenza vaccine is highly immunogenic, prevents virus replication, and protects against severe bronchopneumonia in ferrets",
            "volume": "24"
        },
        "b0060": {
            "authors": [
                {
                    "first": "I. A.",
                    "initial": "I.A.",
                    "last": "Desheva"
                },
                {
                    "first": "T. A.",
                    "initial": "T.A.",
                    "last": "Smolonogina"
                },
                {
                    "first": "M. V.",
                    "initial": "M.V.",
                    "last": "Sergeeva"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Rekstin"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Swayne"
                },
                {
                    "first": "A. I.",
                    "initial": "A.I.",
                    "last": "Klimov"
                },
                {
                    "first": "L. G.",
                    "initial": "L.G.",
                    "last": "Rudenko"
                }
            ],
            "firstpage": "31",
            "issn": "03729311",
            "lastpage": "36",
            "pmid": "19340965",
            "pub_year": 2009,
            "title": "Study of biological properties of cold-adapted reassortant strain of influenza virus subtype H7N3"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Koert J.",
                    "initial": "K.J.",
                    "last": "Stittelaar"
                },
                {
                    "first": "Edwin J.B.",
                    "initial": "E.J.B.",
                    "last": "Veldhuis Kroeze"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Rajeev",
                    "initial": "R.",
                    "last": "Dhere"
                },
                {
                    "first": "Sit",
                    "initial": "S.",
                    "last": "Thirapakpoomanunt"
                },
                {
                    "first": "Marie Paule",
                    "initial": "M.P.",
                    "last": "Kieny"
                },
                {
                    "first": "Albert D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaus"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.09.049",
            "firstpage": "9265",
            "issn": "0264410X",
            "lastpage": "9270",
            "pmid": "21945964",
            "pub_year": 2011,
            "title": "Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets",
            "volume": "29"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Kortney M.",
                    "initial": "K.M.",
                    "last": "Gustin"
                },
                {
                    "first": "Taronna R.",
                    "initial": "T.R.",
                    "last": "Maines"
                },
                {
                    "first": "Jessica A.",
                    "initial": "J.A.",
                    "last": "Belser"
                },
                {
                    "first": "Neal",
                    "initial": "N.",
                    "last": "Van Hoeven"
                },
                {
                    "first": "Xuihua",
                    "initial": "X.",
                    "last": "Lu"
                },
                {
                    "first": "Libo",
                    "initial": "L.",
                    "last": "Dong"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Li Mei",
                    "initial": "L.M.",
                    "last": "Chen"
                },
                {
                    "first": "J. Theo M.",
                    "initial": "J.T.M.",
                    "last": "Voeten"
                },
                {
                    "first": "Jacco G.M.",
                    "initial": "J.G.M.",
                    "last": "Heldens"
                },
                {
                    "first": "Han",
                    "initial": "H.",
                    "last": "Van Den Bosch"
                },
                {
                    "first": "Nancy J.",
                    "initial": "N.J.",
                    "last": "Cox"
                },
                {
                    "first": "Terrence M.",
                    "initial": "T.M.",
                    "last": "Tumpey"
                },
                {
                    "first": "Alexander I.",
                    "initial": "A.I.",
                    "last": "Klimov"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Ruben O.",
                    "initial": "R.O.",
                    "last": "Donis"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Katz"
                }
            ],
            "doi": "10.1093/infdis/jir596",
            "firstpage": "1491",
            "issn": "00221899",
            "lastpage": "1499",
            "pmid": "21957153",
            "pub_year": 2011,
            "title": "Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets",
            "volume": "204"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Andrey",
                    "initial": "A.",
                    "last": "Rekstin"
                },
                {
                    "first": "Yulia",
                    "initial": "Y.",
                    "last": "Desheva"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Ted",
                    "initial": "T.",
                    "last": "Ross"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Swayne"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                }
            ],
            "firstpage": "154",
            "issn": "18742858",
            "lastpage": "162",
            "pub_year": 2014,
            "title": "Live attenuated influenza H7N3 vaccine is safe, immunogenic and confers protection in animal models",
            "volume": "8"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Donald M.",
                    "initial": "D.M.",
                    "last": "Carter"
                },
                {
                    "first": "Chalise E.",
                    "initial": "C.E.",
                    "last": "Bloom"
                },
                {
                    "first": "Greg A.",
                    "initial": "G.A.",
                    "last": "Kirchenbaum"
                },
                {
                    "first": "Vadim",
                    "initial": "V.",
                    "last": "Tsvetnitsky"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Ted M.",
                    "initial": "T.M.",
                    "last": "Ross"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.11.008",
            "firstpage": "108",
            "issn": "0264410X",
            "lastpage": "116",
            "pmid": "25448100",
            "pub_year": 2015,
            "title": "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine",
            "volume": "33"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Anatoly N.",
                    "initial": "A.N.",
                    "last": "Naykhin"
                },
                {
                    "first": "Marianna",
                    "initial": "M.",
                    "last": "Erofeeva"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Stukova"
                },
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Donina"
                },
                {
                    "first": "Galina",
                    "initial": "G.",
                    "last": "Petukhova"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Pisareva"
                },
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Krivitskaya"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Grudinin"
                },
                {
                    "first": "Zhanna",
                    "initial": "Z.",
                    "last": "Buzitskaya"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Kuznetsova"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Larionova"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Desheva"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Dubrovina"
                },
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Nikiforova"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "Victor"
                },
                {
                    "first": "Kathy",
                    "initial": "K.",
                    "last": "Neuzil"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Flores"
                },
                {
                    "first": "Vadim",
                    "initial": "V.",
                    "last": "Tsvetnitsky"
                },
                {
                    "first": "Oleg",
                    "initial": "O.",
                    "last": "Kiselev"
                }
            ],
            "doi": "10.1371/journal.pone.0087962",
            "issn": "19326203",
            "pmid": "24533064",
            "pub_year": 2014,
            "title": "Assessment of human immune responses to H7 avian influenza virus of pandemic potential: Results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine",
            "volume": "9"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Stukova"
                },
                {
                    "first": "Mariana",
                    "initial": "M.",
                    "last": "Erofeeva"
                },
                {
                    "first": "Anatoly",
                    "initial": "A.",
                    "last": "Naykhin"
                },
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Donina"
                },
                {
                    "first": "Galina",
                    "initial": "G.",
                    "last": "Petukhova"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Kuznetsova"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Tatiana",
                    "initial": "T.",
                    "last": "Smolonogina"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Dubrovina"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Pisareva"
                },
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Nikiforova"
                },
                {
                    "first": "Maureen",
                    "initial": "M.",
                    "last": "Power"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Flores"
                },
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                }
            ],
            "doi": "10.1080/21645515.2015.1010859",
            "firstpage": "970",
            "issn": "21645515",
            "lastpage": "982",
            "pmid": "25831405",
            "pub_year": 2015,
            "title": "H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers",
            "volume": "11"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Stukova"
                },
                {
                    "first": "Marianna",
                    "initial": "M.",
                    "last": "Erofeeva"
                },
                {
                    "first": "Anatoly",
                    "initial": "A.",
                    "last": "Naykhin"
                },
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Donina"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Larionova"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Pisareva"
                },
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Krivitskaya"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Flores"
                },
                {
                    "first": "I. Irina",
                    "initial": "I.I.",
                    "last": "Dubrovina"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Galina",
                    "initial": "G.",
                    "last": "Petukhova"
                },
                {
                    "first": "Ekaterina",
                    "initial": "E.",
                    "last": "Bazhenova"
                },
                {
                    "first": "Tatiana",
                    "initial": "T.",
                    "last": "Smolonogina"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Kuznetsova"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Losev"
                },
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Nikiforova"
                },
                {
                    "first": "Oleg",
                    "initial": "O.",
                    "last": "Kiselev"
                },
                {
                    "first": "Maureen",
                    "initial": "M.",
                    "last": "Power"
                },
                {
                    "first": "Vadim",
                    "initial": "V.",
                    "last": "Tsvetnitsky"
                },
                {
                    "first": "Yuxiao",
                    "initial": "Y.",
                    "last": "Tang"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2015.08.019",
            "firstpage": "5110",
            "issn": "0264410X",
            "lastpage": "5117",
            "pmid": "26296497",
            "pub_year": 2015,
            "title": "Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: Results from a placebo-controlled, randomized double-blind phase I study",
            "volume": "33"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Anatoly",
                    "initial": "A.",
                    "last": "Naykhin"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Stukova"
                },
                {
                    "first": "Mariana",
                    "initial": "M.",
                    "last": "Erofeeva"
                },
                {
                    "first": "Daniil",
                    "initial": "D.",
                    "last": "Korenkov"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Matyushenko"
                },
                {
                    "first": "Erin",
                    "initial": "E.",
                    "last": "Sparrow"
                },
                {
                    "first": "Marie Paule",
                    "initial": "M.P.",
                    "last": "Kieny"
                }
            ],
            "doi": "10.1016/S1473-3099(15)00378-3",
            "firstpage": "303",
            "issn": "14733099",
            "lastpage": "310",
            "pmid": "26673391",
            "pub_year": 2016,
            "title": "H7N9 live attenuated influenza vaccine in healthy adults: A randomised, double-blind, placebo-controlled, phase 1 trial",
            "volume": "16"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Benjaluck",
                    "initial": "B.",
                    "last": "Phonrat"
                },
                {
                    "first": "Punnee",
                    "initial": "P.",
                    "last": "Pitisuttithum"
                },
                {
                    "first": "Supat",
                    "initial": "S.",
                    "last": "Chamnanchanunt"
                },
                {
                    "first": "Pilaipan",
                    "initial": "P.",
                    "last": "Puthavathana"
                },
                {
                    "first": "Nathamon",
                    "initial": "N.",
                    "last": "Ngaosuwankul"
                },
                {
                    "first": "Suda",
                    "initial": "S.",
                    "last": "Louisirirotchanakul"
                },
                {
                    "first": "Jittima",
                    "initial": "J.",
                    "last": "Dhitavat"
                },
                {
                    "first": "Sit",
                    "initial": "S.",
                    "last": "Thirapakpoomanunt"
                },
                {
                    "first": "Vichai",
                    "initial": "V.",
                    "last": "Chokevivat"
                },
                {
                    "first": "Suwit",
                    "initial": "S.",
                    "last": "Wibulpolprasert"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.12.082",
            "firstpage": "1503",
            "issn": "0264410X",
            "lastpage": "1509",
            "pmid": "23318149",
            "pub_year": 2013,
            "title": "Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais",
            "volume": "31"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Rajeev",
                    "initial": "R.",
                    "last": "Dhere"
                },
                {
                    "first": "Leena",
                    "initial": "L.",
                    "last": "Yeolekar"
                },
                {
                    "first": "Prasad",
                    "initial": "P.",
                    "last": "Kulkarni"
                },
                {
                    "first": "Ravi",
                    "initial": "R.",
                    "last": "Menon"
                },
                {
                    "first": "Vivek",
                    "initial": "V.",
                    "last": "Vaidya"
                },
                {
                    "first": "Milan",
                    "initial": "M.",
                    "last": "Ganguly"
                },
                {
                    "first": "Parikshit",
                    "initial": "P.",
                    "last": "Tyagi"
                },
                {
                    "first": "Prajakt",
                    "initial": "P.",
                    "last": "Barde"
                },
                {
                    "first": "Suresh",
                    "initial": "S.",
                    "last": "Jadhav"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.04.119",
            "firstpage": "A16",
            "issn": "0264410X",
            "lastpage": "A21",
            "pmid": "21684421",
            "pub_year": 2011,
            "title": "A pandemic influenza vaccine in India: From strain to sale within 12 months",
            "volume": "29"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Prasad S.",
                    "initial": "P.S.",
                    "last": "Kulkarni"
                },
                {
                    "first": "Sidram K.",
                    "initial": "S.K.",
                    "last": "Raut"
                },
                {
                    "first": "Rajeev M.",
                    "initial": "R.M.",
                    "last": "Dhere"
                }
            ],
            "doi": "10.4161/hv.22317",
            "firstpage": "122",
            "issn": "21645515",
            "lastpage": "124",
            "pmid": "23442586",
            "pub_year": 2013,
            "title": "A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac\u00ae) in India",
            "volume": "9"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Prasad S.",
                    "initial": "P.S.",
                    "last": "Kulkarni"
                },
                {
                    "first": "Sharad",
                    "initial": "S.",
                    "last": "Agarkhedkar"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Lalwani"
                },
                {
                    "first": "Ashish R.",
                    "initial": "A.R.",
                    "last": "Bavdekar"
                },
                {
                    "first": "Sameer",
                    "initial": "S.",
                    "last": "Jog"
                },
                {
                    "first": "Sidram K.",
                    "initial": "S.K.",
                    "last": "Raut"
                },
                {
                    "first": "Varsha",
                    "initial": "V.",
                    "last": "Parulekar"
                },
                {
                    "first": "Shalaka S.",
                    "initial": "S.S.",
                    "last": "Agarkhedkar"
                },
                {
                    "first": "Sonali",
                    "initial": "S.",
                    "last": "Palkar"
                },
                {
                    "first": "Somnath",
                    "initial": "S.",
                    "last": "Mangrule"
                }
            ],
            "doi": "10.4161/hv.27490",
            "firstpage": "566",
            "issn": "21645515",
            "lastpage": "571",
            "pmid": "24406308",
            "pub_year": 2014,
            "title": "Effectiveness of an Indian-made attenuated influenza A(H1N1)pdm 2009 vaccine: A case control study",
            "volume": "10"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Justin R.",
                    "initial": "J.R.",
                    "last": "Ortiz"
                },
                {
                    "first": "Doli",
                    "initial": "D.",
                    "last": "Goswami"
                },
                {
                    "first": "Kristen D.C.",
                    "initial": "K.D.C.",
                    "last": "Lewis"
                },
                {
                    "first": "Amina Tahia",
                    "initial": "A.T.",
                    "last": "Sharmeen"
                },
                {
                    "first": "Moshtaq",
                    "initial": "M.",
                    "last": "Ahmed"
                },
                {
                    "first": "Mustafizur",
                    "initial": "M.",
                    "last": "Rahman"
                },
                {
                    "first": "Mohammed Z.",
                    "initial": "M.Z.",
                    "last": "Rahman"
                },
                {
                    "first": "Jodi",
                    "initial": "J.",
                    "last": "Feser"
                },
                {
                    "first": "Kathleen M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "W. Abdullah",
                    "initial": "W.A.",
                    "last": "Brooks"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.04.048",
            "firstpage": "3415",
            "issn": "0264410X",
            "lastpage": "3421",
            "pmid": "25917680",
            "pub_year": 2015,
            "title": "Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh",
            "volume": "33"
        }
    },
    "body_text": [
        {
            "endOffset": 27170,
            "parents": [],
            "secId": "s0030",
            "sentence": "Since the development of LAIV at SIIPL five different compositions recommended for the northern and southern hemisphere have been manufactured and used successfully (Table 4).",
            "startOffset": 26995,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 15859,
            "parents": [],
            "secId": "s0005",
            "sentence": "In Russia, LAIV has a long history of development, stage-wise improvement, licensing and use in public health.",
            "startOffset": 15749,
            "title": "Introduction"
        },
        {
            "endOffset": 19281,
            "parents": [],
            "secId": "s0010",
            "sentence": "The organizations responsible for this were WHO, the Biomedical Advanced Research and Development Authority (BARDA), USA, and IEM.",
            "startOffset": 19151,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 25753,
            "parents": [],
            "secId": "s0030",
            "sentence": "Clinical experience with the monovalent H1N1pdm09 LAIV showed a good safety profile of the vaccine in all age groups, including children aged over 3 years.",
            "startOffset": 25598,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 28661,
            "parents": [],
            "secId": "s0030",
            "sentence": "To make the delivery user-friendly, the quadrivalent vaccine has been developed as a ready-to-use liquid vaccine and the nasal delivery devices have been upgraded.",
            "startOffset": 28498,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 20563,
            "parents": [],
            "secId": "s0015",
            "sentence": "Additional financing for the purchase of the equipment was provided by the Program for Appropriate Technologies in Health (PATH), Seattle, Washington, USA.",
            "startOffset": 20408,
            "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
        },
        {
            "endOffset": 22759,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "In order to minimize the potential for vaccine virus to release into the environment vaccinations took place in an inpatient isolation unit; subjects were tested for influenza virus in nasal swabs prior to vaccination; presence of vaccine virus in nasal swabs was assessed daily; subjects were to be kept in the isolation unit until shedding was no longer detected; an independent Safety Monitoring Committee reviewed the safety and shedding data.",
            "startOffset": 22312,
            "title": "Clinical trials"
        },
        {
            "endOffset": 28214,
            "parents": [],
            "secId": "s0030",
            "sentence": "Twice per year WHO recommends the composition of strains for both trivalent and quadrivalent vaccines.",
            "startOffset": 28112,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 24409,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "In contrast, none of the placebo recipients exhibited any response (Fig. 1).",
            "startOffset": 24333,
            "title": "Clinical trials"
        },
        {
            "endOffset": 25465,
            "parents": [],
            "secId": "s0030",
            "sentence": "SIIPL developed a lyophilized monovalent H1N1pdm09 LAIV that was reconstituted with water for inhalation; it showed satisfactory stability of 9 months.",
            "startOffset": 25314,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 27982,
            "parents": [],
            "secId": "s0030",
            "sentence": "Furthermore, an age de-escalation study aimed at immunizing children aged 6\u201324 months is under consideration.",
            "startOffset": 27873,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 28111,
            "parents": [],
            "secId": "s0030",
            "sentence": "Some manufacturers are now producing quadrivalent vaccines to include both lineages of influenza type B which are co-circulating.",
            "startOffset": 27982,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 32298,
            "parents": [],
            "secId": "s0045",
            "sentence": "The studies were supported by PATH and WHO.",
            "startOffset": 32255,
            "title": "Financial disclosure"
        },
        {
            "endOffset": 29041,
            "parents": [],
            "secId": "s0030",
            "sentence": "A well-characterized Madin-Darby canine kidney (MDCK) cell bank has been prepared by SIIPL and experimental batches have been prepared.",
            "startOffset": 28906,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 25190,
            "parents": [],
            "secId": "s0030",
            "sentence": "In 2011, the BCHT signed an agreement with WHO, and since then the company has built a manufacturing plant and adopted the LAIV production technology.",
            "startOffset": 25040,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 16396,
            "parents": [],
            "secId": "s0005",
            "sentence": "Russian LAIV has been shown through studies to consistently provide superior effective protection, especially in children, compared to IIV.",
            "startOffset": 16257,
            "title": "Introduction"
        },
        {
            "endOffset": 26995,
            "parents": [],
            "secId": "s0030",
            "sentence": "The vaccine was licensed by the Indian authorities in January 2014 and is prequalified by WHO.",
            "startOffset": 26901,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 27872,
            "parents": [],
            "secId": "s0030",
            "sentence": "This trial is in its second year of immunization and is expected to be completed by mid 2017.",
            "startOffset": 27779,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 25261,
            "parents": [],
            "secId": "s0030",
            "sentence": "BCHT is currently conducting Phase I clinical trials of seasonal LAIV.",
            "startOffset": 25191,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 26004,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 26003,
                    "startOffset": 25999
                }
            },
            "secId": "s0030",
            "sentence": "Post-marketing surveillance and the periodic safety update reports further established the safety of the vaccine [23].",
            "startOffset": 25886,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 15996,
            "parents": [],
            "secId": "s0005",
            "sentence": "Since 1987, Russian LAIV has been used for the prophylaxis of influenza in children aged over three years, in adults and in the elderly.",
            "startOffset": 15860,
            "title": "Introduction"
        },
        {
            "endOffset": 23335,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "The vaccine viruses were recovered from the nasal or throat swabs of vaccinees by virus culture in embryonated eggs, with most of the subjects scoring positive for virus shedding only on the first day after vaccination.",
            "startOffset": 23116,
            "title": "Clinical trials"
        },
        {
            "endOffset": 29334,
            "parents": [],
            "secId": "s0030",
            "sentence": "The SIIPL is aiming towards a MDCK-based quadrivalent liquid LAIV that will have an ideal influenza vaccine profile including safety, efficacy, stability and ease of administration, as well as high capacity to rapidly increase the production.",
            "startOffset": 29092,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 15215,
            "parents": [],
            "secId": "s0005",
            "sentence": "These factors make LAIV especially attractive for developing countries with a large population.",
            "startOffset": 15120,
            "title": "Introduction"
        },
        {
            "endOffset": 15422,
            "parents": [],
            "secId": "s0005",
            "sentence": "Furthermore, the concept of replicating the vaccine virus in the nasal cavity and thus generating a specific immune response at the site of infection appears to be the most appropriate mode of immunization.",
            "startOffset": 15216,
            "title": "Introduction"
        },
        {
            "endOffset": 24895,
            "parents": [],
            "secId": "s0030",
            "sentence": "Since the registration of H1N1pdm09 LAIV, intensive studies of another pre-pandemic LAIV candidate \u2013 H5N2 \u2013 have been carried out at GPO.",
            "startOffset": 24758,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 23686,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "Importantly, the lack of vaccine virus transmission to placebo recipients was observed despite co-housing all subjects (vaccine and placebo recipients) in the same isolation facility.",
            "startOffset": 23503,
            "title": "Clinical trials"
        },
        {
            "endOffset": 23502,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "No vaccine virus or viral RNA was detected in any of the placebo recipients after either the first or the second vaccine dose for any of the five LAIVs reported here.",
            "startOffset": 23336,
            "title": "Clinical trials"
        },
        {
            "endOffset": 20161,
            "parents": [],
            "secId": "s0015",
            "sentence": "For this purpose WHO, in collaboration with BARDA, allocated all necessary funds, and the construction was completed in 2014.",
            "startOffset": 20036,
            "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
        },
        {
            "endOffset": 23990,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "Immunization with potentially pandemic LAIVs induced high levels of hemagglutination inhibition (HAI) and local secretory antibodies, as well as long-lasting B-cell immunological memory against antigenically related influenza virus.",
            "startOffset": 23758,
            "title": "Clinical trials"
        },
        {
            "endOffset": 20035,
            "parents": [],
            "secId": "s0015",
            "sentence": "To meet the demand for high-quality LAIV seed viruses for further distribution between dedicated manufacturers, it was necessary to reconstruct and build a new state-of-the-art facility at IEM to work with pathogens of biosafety level BSL-2 and BSL-3 groups, in compliance with all international biosafety standards.",
            "startOffset": 19719,
            "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
        },
        {
            "endOffset": 25040,
            "parents": [],
            "secId": "s0030",
            "sentence": "Thus, Thailand is well on the way to having LAIVs ready to respond to a pandemic.",
            "startOffset": 24959,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 15559,
            "parents": [],
            "secId": "s0005",
            "sentence": "All these features of LAIV become even more relevant with the emergence of potentially pandemic influenza viruses of different serotypes.",
            "startOffset": 15422,
            "title": "Introduction"
        },
        {
            "endOffset": 27778,
            "parents": [],
            "secId": "s0030",
            "sentence": "One more clinical trial of seasonal LAIV by the CDC is ongoing in children at Ballabgarh, Haryana, India (see vaccine composition in Table 4).",
            "startOffset": 27636,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 22861,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 22860,
                    "startOffset": 22851
                },
                "b0085": {
                    "endOffset": 22860,
                    "startOffset": 22851
                },
                "b0090": {
                    "endOffset": 22860,
                    "startOffset": 22851
                },
                "b0095": {
                    "endOffset": 22860,
                    "startOffset": 22851
                },
                "b0100": {
                    "endOffset": 22860,
                    "startOffset": 22851
                }
            },
            "secId": "s0025",
            "sentence": "These LAIVs were found to be safe, well tolerated and immunogenic in human adult volunteers [4,17\u201320].",
            "startOffset": 22759,
            "title": "Clinical trials"
        },
        {
            "endOffset": 27290,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 27289,
                    "startOffset": 27285
                }
            },
            "secId": "s0030",
            "sentence": "Two clinical trials to assess efficacy in children aged 2\u20135 years were conducted by PATH in Bangladesh and Senegal [25].",
            "startOffset": 27170,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 26639,
            "parents": [],
            "secId": "s0030",
            "sentence": "Understanding this need, SIIPL ventured into development of a seasonal trivalent LAIV, prepared using the same manufacturing process and stabilizer as the monovalent H1N1pdm09LAIV, and with a stability of 9 months.",
            "startOffset": 26425,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 28905,
            "parents": [],
            "secId": "s0030",
            "sentence": "An obvious solution to this problem is the development of a tissue culture-based LAIV.",
            "startOffset": 28819,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 22311,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "All trials were randomized, double-blinded, placebo-controlled studies in healthy adults.",
            "startOffset": 22222,
            "title": "Clinical trials"
        },
        {
            "endOffset": 29092,
            "parents": [],
            "secId": "s0030",
            "sentence": "Further work to develop GMP LAIV lots is underway.",
            "startOffset": 29042,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 21775,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0020",
            "sentence": "It was demonstrated that immunization with the potentially pandemic LAIV candidates induced a strong immune response, and the ferrets were protected against homologous and heterologous wild-type virus challenge.",
            "startOffset": 21564,
            "title": "Preclinical testing"
        },
        {
            "endOffset": 22005,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0020",
            "sentence": "Replication of challenge viruses in the upper and lower respiratory tracts of immunized animals was significantly reduced compared to the controls, and no signs of disease were observed in any of the vaccinated animals (Table 3).",
            "startOffset": 21776,
            "title": "Preclinical testing"
        },
        {
            "endOffset": 18813,
            "parents": [],
            "secId": "s0010",
            "sentence": "All of these LAIV candidates were accompanied by strain certificates drawn up in accordance with international standards, which included detailed descriptions of the seed-LAIV generation and the quality-control attributes; that is, antigenicity and identity tests, phenotypic and propagation characteristics, genetic stability data, full genome sequencing, sterility control and safety preclinical testing in laboratory animals.",
            "startOffset": 18385,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 23115,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "The frequency of reporting sore throat following LAIV administration ranged from 11% (for H2N2 LAIV) to 27% (for H7N3 LAIV).",
            "startOffset": 22991,
            "title": "Clinical trials"
        },
        {
            "endOffset": 18189,
            "parents": [],
            "secId": "s0010",
            "sentence": "Under this agreement, there were two main areas of work: development of seasonal LAIV candidates according to biannual WHO recommendations for influenza vaccine compositions, and Development of LAIV candidates against potentially pandemic influenza viruses.",
            "startOffset": 17932,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 24757,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 24756,
                    "startOffset": 24752
                }
            },
            "secId": "s0030",
            "sentence": "Using LAIV production technology adapted from IEM, GPO successfully produced H1N1pdm09 LAIV, conducted preclinical and clinical trials of this vaccine, and registered it in 2011 [21].",
            "startOffset": 24574,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 20407,
            "parents": [],
            "secId": "s0015",
            "sentence": "This laboratory occupies a total area of 550 m2, with additional technical and engineering facilities covering an area of over 1000 m2.",
            "startOffset": 20272,
            "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
        },
        {
            "endOffset": 17410,
            "parents": [],
            "secId": "s0010",
            "sentence": "The agreement with BioDiem permitted WHO to grant sub-licenses to vaccine manufacturers in the newly industrialized countries (NICs) and developing countries within the framework of the WHO influenza vaccine technology transfer project.",
            "startOffset": 17174,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 24574,
            "parents": [],
            "secId": "s0030",
            "sentence": "The declaration of 2009 H1N1 influenza pandemic prompted SIIPL and GPO to start immediate manufacturing of pandemic LAIV.",
            "startOffset": 24453,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 26301,
            "parents": [],
            "secId": "s0030",
            "sentence": "One of the major issues related to pandemic preparedness is the availability of a pre-existing manufacturing setup that can be geared up for large-scale vaccine production in the face of a pandemic.",
            "startOffset": 26103,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 22221,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "Phase I clinical trials of the potentially pandemic LAIV candidates of H5N2, H7N3, H2N2 and H7N9 subtypes were conducted in clinics of the Research Institute of Influenza (Saint Petersburg, Russia).",
            "startOffset": 22023,
            "title": "Clinical trials"
        },
        {
            "endOffset": 14523,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 14522,
                    "startOffset": 14519
                }
            },
            "secId": "s0005",
            "sentence": "Influenza is a life-threatening viral infection that may affect up to 40% of the world\u2019s population each year [1].",
            "startOffset": 14409,
            "title": "Introduction"
        },
        {
            "endOffset": 21090,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 20967,
                    "startOffset": 20964
                },
                "b0050": {
                    "endOffset": 21003,
                    "startOffset": 20999
                },
                "b0055": {
                    "endOffset": 21035,
                    "startOffset": 21031
                },
                "b0060": {
                    "endOffset": 21079,
                    "startOffset": 21075
                }
            },
            "secId": "s0015",
            "sentence": "According to collaborative agreements between IEM, PATH and WHO, the following potentially pandemic LAIV candidates were developed: A/17/turkey/Turkey/05/133 (H5N2) [9], A/17/Vietnam/04/65107 (H5N2) [9], A/17/California/66/395 (H2N2) [10], A/17/Anhui/2013/61 (H7N9) [11], A/17/mallard/Netherlands/00/95 (H7N3) [12] (Table 2).",
            "startOffset": 20765,
            "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
        },
        {
            "endOffset": 26748,
            "parents": [],
            "secId": "s0030",
            "sentence": "The trivalent LAIV was tested in a ferret challenge study, and established protection from all three strains.",
            "startOffset": 26639,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 17750,
            "parents": [],
            "secId": "s0010",
            "sentence": "Since 2009, WHO has signed agreements with the Changchun BCHT Biotechnology Co., Ltd. (BCHT, Changchun, Jilin, China), the Serum Institute of India Pvt. Ltd. (SIIPL, Pune, India) and the Government Pharmaceutical Organization (GPO, Bangkok, Thailand) for the development, manufacture, use and sale of the egg-based LAIV using Russian MDVs.",
            "startOffset": 17411,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 26900,
            "parents": [],
            "secId": "s0030",
            "sentence": "The clinical trials involved safety assessment and immunogenicity testing in individuals aged over 2 years, which both demonstrated acceptable results.",
            "startOffset": 26749,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 24332,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "Taking into account all the assays conducted (HAI, microneutralization, enzyme-linked immunosorbent assay [ELISA] and cytokine flow cytometry), an immune response was observed in 70.2% of H1N1pdm09-LAIV recipients, 96.6% of H5N2-LAIV recipients, 86.2% of H7N3-LAIV recipients, 92.6% of H2N2-LAIV recipients and 93.1% of H7N9-LAIV recipients.",
            "startOffset": 23991,
            "title": "Clinical trials"
        },
        {
            "endOffset": 16748,
            "parents": [],
            "secId": "s0005",
            "sentence": "Some recent studies have however suggested that since 2011 there has been a reduction in the comparative efficacy of the Ann-Arbor based LAIV compared to IIV.",
            "startOffset": 16590,
            "title": "Introduction"
        },
        {
            "endOffset": 22990,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "Catarrhal symptoms, such as hyperemia and sore throat, were the most frequently reported adverse events with the pandemic LAIVs.",
            "startOffset": 22862,
            "title": "Clinical trials"
        },
        {
            "endOffset": 27636,
            "parents": [],
            "secId": "s0030",
            "sentence": "These contrasting findings are difficult to explain and need extensive analysis on antigenic make up of the circulating strains, population behavior and so on.",
            "startOffset": 27477,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 21563,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 21562,
                    "startOffset": 21550
                },
                "b0050": {
                    "endOffset": 21562,
                    "startOffset": 21550
                },
                "b0055": {
                    "endOffset": 21562,
                    "startOffset": 21550
                },
                "b0065": {
                    "endOffset": 21562,
                    "startOffset": 21550
                },
                "b0070": {
                    "endOffset": 21562,
                    "startOffset": 21550
                },
                "b0075": {
                    "endOffset": 21562,
                    "startOffset": 21550
                },
                "b0080": {
                    "endOffset": 21562,
                    "startOffset": 21550
                }
            },
            "secId": "s0020",
            "sentence": "Studies on the safety, immunogenicity and protective efficacy of these potentially pandemic LAIV candidates in ferrets were conducted in collaboration with experts from the Centre for Infectious Disease Control (Bilthoven, Netherlands), University of Pittsburgh (Pittsburgh, Pennsylvania, USA), Southeast Poultry Research Laboratory (Athens, Georgia, USA), CDC (Atlanta, Georgia, USA) and ViroClinics Biosciences (Rotterdam, Netherlands) [9\u201311,13\u201316].",
            "startOffset": 21112,
            "title": "Preclinical testing"
        },
        {
            "endOffset": 17173,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 17172,
                    "startOffset": 17169
                }
            },
            "secId": "s0010",
            "sentence": "BioDiem Ltd. (Melbourne, Australia), holding the rights for use of the Russian MDVs, licensed Russian LAIV technology to WHO [4].",
            "startOffset": 17044,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 16589,
            "parents": [],
            "secId": "s0005",
            "sentence": "The other LAIV used in the world, based on Ann-Arbor backbone has likewise been shown to provide superior protective efficacy in children, compared to IIV, through randomized controlled trials.",
            "startOffset": 16396,
            "title": "Introduction"
        },
        {
            "endOffset": 14832,
            "parents": [],
            "secId": "s0005",
            "sentence": "Long-term observations have shown that live attenuated influenza vaccine (LAIV) has some major advantages over inactivated influenza vaccine (IIV).",
            "startOffset": 14685,
            "title": "Introduction"
        },
        {
            "endOffset": 25313,
            "parents": [],
            "secId": "s0030",
            "sentence": "The LAIV promotion in India was the most successful.",
            "startOffset": 25261,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 15749,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 15748,
                    "startOffset": 15743
                },
                "b0015": {
                    "endOffset": 15748,
                    "startOffset": 15743
                }
            },
            "secId": "s0005",
            "sentence": "The World Health Organization (WHO) recognized the advantages of LAIV over IIV in the event of a pandemic and therefore included LAIV in its Global action plan for influenza vaccines [2,3].",
            "startOffset": 15560,
            "title": "Introduction"
        },
        {
            "endOffset": 25807,
            "parents": [],
            "secId": "s0030",
            "sentence": "The immune response was in line with the other LAIVs.",
            "startOffset": 25754,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 17008,
            "parents": [],
            "secId": "s0005",
            "sentence": "The cause is still unknown however efforts to understand this sudden loss of efficacy are focusing on the role of the A/California H1N1 component as well as the inclusion of a second B-strain, and it is expected that this issue will be successfully addressed.",
            "startOffset": 16749,
            "title": "Introduction"
        },
        {
            "endOffset": 17931,
            "parents": [],
            "secId": "s0010",
            "sentence": "At the same time, the Institute of Experimental Medicine (IEM), Saint Petersburg, Russia \u2013 the sole developer of reassortant strains for Russian LAIV \u2013 signed an agreement with WHO.",
            "startOffset": 17750,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 28497,
            "parents": [],
            "secId": "s0030",
            "sentence": "Further efforts are being made to develop rapid up scaling capacity for the vaccine production during a pandemic.",
            "startOffset": 28384,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 15119,
            "parents": [],
            "secId": "s0005",
            "sentence": "These advantages include ease of needle-free delivery, extremely low rate of adverse reactions, smaller infrastructure requirement for manufacturing, limited downstream processing and significantly higher yield in eggs (nearly 15 doses of LAIV can be produced from one embryonated egg).",
            "startOffset": 14833,
            "title": "Introduction"
        },
        {
            "endOffset": 20271,
            "parents": [],
            "secId": "s0015",
            "sentence": "Since then, the facility has been fully operational and has been certified by the Russian Ministry of Health.",
            "startOffset": 20162,
            "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
        },
        {
            "endOffset": 23758,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
                }
            ],
            "secId": "s0025",
            "sentence": "This finding may support the lack of vaccine transmissibility of LAIVs.",
            "startOffset": 23687,
            "title": "Clinical trials"
        },
        {
            "endOffset": 27363,
            "parents": [],
            "secId": "s0030",
            "sentence": "The vaccine was found to be efficacious in this age group in Bangladesh.",
            "startOffset": 27291,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 27476,
            "parents": [],
            "secId": "s0030",
            "sentence": "Surprisingly, the Senegal study indicated no protection in the same age group using the same lot of the vaccine.",
            "startOffset": 27364,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 14685,
            "parents": [],
            "secId": "s0005",
            "sentence": "Vaccination remains the most effective means of preventing seasonal influenza epidemics, which are associated with significant morbidity and mortality worldwide.",
            "startOffset": 14524,
            "title": "Introduction"
        },
        {
            "endOffset": 19593,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 19499,
                    "startOffset": 19494
                },
                "b0030": {
                    "endOffset": 19499,
                    "startOffset": 19494
                },
                "b0035": {
                    "endOffset": 19499,
                    "startOffset": 19494
                },
                "b0040": {
                    "endOffset": 19499,
                    "startOffset": 19494
                }
            },
            "secId": "s0010",
            "sentence": "The back-up laboratory has been working successfully [5\u20138] and a number of reassortants have been used to produce the LAIV in India and China (Table 4).",
            "startOffset": 19441,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 18384,
            "parents": [],
            "secId": "s0010",
            "sentence": "During the period 2009\u20132015, IEM developed and transferred to WHO nine seed-LAIVs for seasonal vaccines and one H1N1 pandemic seed-LAIV for further distribution to manufacturers (Tables 1 and 2).",
            "startOffset": 18189,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 26103,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 26102,
                    "startOffset": 26098
                }
            },
            "secId": "s0030",
            "sentence": "A case-control study also demonstrated high effectiveness of the vaccine during the epidemic [24].",
            "startOffset": 26005,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 25885,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 25884,
                    "startOffset": 25880
                }
            },
            "secId": "s0030",
            "sentence": "The vaccine was developed, licensed and commercialized within 12 months [22].",
            "startOffset": 25808,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 20764,
            "parents": [],
            "secId": "s0015",
            "sentence": "Including the LAIV into the WHO Global action plan for influenza vaccines required the generation of a panel of LAIV candidates against potentially pandemic H5N1, H2N2, H7N9 and H7N3 influenza viruses.",
            "startOffset": 20563,
            "title": "Creation of a modern high-tech pathogenic agent\u2019s laboratory facility and development of potentially pandemic LAIV candidates"
        },
        {
            "endOffset": 26424,
            "parents": [],
            "secId": "s0030",
            "sentence": "This would be possible only if continual manufacturing of the influenza vaccine for the annual vaccination was maintained.",
            "startOffset": 26302,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 16256,
            "parents": [],
            "secId": "s0005",
            "sentence": "Currently, reassortant viruses for Russian LAIV are prepared by classical reassortment in eggs of wild-type influenza A and B viruses with two cold-adapted master donor viruses (MDVs) as a backbone: A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69, respectively.",
            "startOffset": 15997,
            "title": "Introduction"
        },
        {
            "endOffset": 28818,
            "parents": [],
            "secId": "s0030",
            "sentence": "Considering the unpredictable demand for influenza vaccines in India, and worldwide in general, pre-ordering for large quantity of eggs is a major challenge.",
            "startOffset": 28661,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 25598,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 25597,
                    "startOffset": 25593
                }
            },
            "secId": "s0030",
            "sentence": "Preclinical studies in ferrets showed remarkable protection after challenge with wild-type virus, with one dose of the vaccine [13].",
            "startOffset": 25466,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 32235,
            "parents": [],
            "secId": "s0040",
            "sentence": "All the authors have declared that have no conflict of interest, except for LeenaYeolekar who is an employee of SIIPL.",
            "startOffset": 32117,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 24958,
            "parents": [],
            "secId": "s0030",
            "sentence": "These studies are progressing well and are nearing completion.",
            "startOffset": 24896,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 28384,
            "parents": [],
            "secId": "s0030",
            "sentence": "SIIPL developed a good manufacturing practice (GMP)-grade egg-based quadrivalent preparation of LAIV that was tested in the ferret model for immunogenicity and efficacy.",
            "startOffset": 28215,
            "title": "Progress of development of LAIV in the NICs"
        },
        {
            "endOffset": 19440,
            "parents": [],
            "secId": "s0010",
            "sentence": "This decision made it possible to reduce the unpredictable risks associated with the production of LAIV candidates in one laboratory and in one country alone.",
            "startOffset": 19282,
            "title": "Transfer of Russian LAIV technology"
        },
        {
            "endOffset": 19150,
            "parents": [],
            "secId": "s0010",
            "sentence": "In 2012, the increased international demand for the Russian LAIV prompted the establishment of an additional (back-up) laboratory facility at the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America (USA) for parallel preparation of the LAIV candidates based on Russian MDVs for international use.",
            "startOffset": 18813,
            "title": "Transfer of Russian LAIV technology"
        }
    ],
    "docId": "S0264410X16306752",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "vaccine@mail.ru",
                "first": "Larisa",
                "initial": "L.",
                "last": "Rudenko"
            },
            {
                "email": "leena.yeolekar@seruminstitute.com",
                "first": "Leena",
                "initial": "L.",
                "last": "Yeolekar"
            },
            {
                "email": "irina.v.kiseleva@mail.ru",
                "first": "Irina",
                "initial": "I.",
                "last": "Kiseleva"
            },
            {
                "email": "isakova.sivak@gmail.com",
                "first": "Irina",
                "initial": "I.",
                "last": "Isakova-Sivak"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.08.018",
        "firstpage": "5436",
        "issn": "0264410X",
        "keywords": [
            "Clinical trials",
            "Influenza",
            "Live attenuated influenza vaccine",
            "Pandemic preparedness",
            "Potentially pandemic viruses",
            "Preclinical studies",
            "Seasonal vaccine",
            "Technology transfer"
        ],
        "lastpage": "5441",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories"
    }
}